πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8906870

MicroRNA (miRNA) for the diagnosis and treatment of heart diseases

Julius-Maximilians-Universitat Wurzburg Β· Granted Tue Dec 09 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8906853

[N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis

Enanta Pharmaceuticals, Inc. Β· Granted Tue Dec 09 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8901309

Fused triazoles for the treatment or prophylaxis of mild cognitive impairment

Takeda Pharmaceutical Company Limited Β· Granted Tue Dec 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8901173

Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Jazz Pharmaceuticals, Inc. Β· Granted Tue Dec 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8900574

Mesenchymal stem cells for the treatment of CNS diseases

BRAINSTORM CELL THERAPEUTICS LTD. Β· Granted Tue Dec 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8895521

Methods and compositions for the treatment of uveitis

The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Tue Nov 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8895579

Heterotricyclic AMPA receptor antagonists for treatment of epilepsy, pain, and other neuro

Northwestern University Β· Granted Tue Nov 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8895539

Pregnancy hormone combination for treatment of autoimmune diseases

The Regents of the University of California Β· Granted Tue Nov 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8895018

Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric imp

The United States of America as represented by the Department of Veteran Affairs Β· Granted Tue Nov 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8889627

Treatment of multiple sclerosis with combination of laquinimod and fingolimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8889661

Treatment of lupus nephritis using laquinimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8883144

Treatment of pulmonary vascular remodeling with neprilysin

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Nov 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8875970

Structure containing wound treatment material

Covidien LP Β· Granted Tue Nov 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8877765

Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer

The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Tue Nov 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8877204

Methods and compositions for the treatment of cancer and infectious disease using alpha (2

University of Connecticut Health Center Β· Granted Tue Nov 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8877188

Detection and treatment of non-dermal fibrosis

The Board of Regents of the University of Texas System Β· Granted Tue Nov 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8871925

Compositions of novel carbohydrate drug for treatment of human diseases

GALECTIN THERAPEUTICS, INC. Β· Granted Tue Oct 28 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8865694

Topical compositions for treatment of skin conditions

Molecular Design International, Inc. Β· Granted Tue Oct 21 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8859585

Scopolamine for the treatment of depression and anxiety

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Oct 14 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8859619

Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatme

Jazz Pharmaceuticals, Inc. Β· Granted Tue Oct 14 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8859527

Inclusion complex of deoxypodophyllotoxin of cyclodextrin, preparation method, use for tre

CHINA PHARMACEUTICAL UNIVERSITY Β· Granted Tue Oct 14 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8853215

Derivatives of N-acyl-Nβ€²-phenylpiperazine useful (inter alia) for the prophylaxis or treat

Takeda Pharmaceutical Company Limited Β· Granted Tue Oct 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8853277

Nitroxide therapy for the treatment of von Hippelβ€”Lindau disease (VHL) and renal clear cel

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Oct 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8852626

Controlled-release CNS modulating compositions and methods for the treatment of otic disor

The Regents of the University of California Β· Granted Tue Oct 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted